January 4th 2022
By Tony Hagen
Savings from adalimumab biosimilars, which won't enter the US market until 2023, account for a significant share of the total, investigators said.
January 1st 2022
Biosimilars have produced more than $20 billion of savings in Europe, but more use of these agents is needed.
December 31st 2021
The top legal stories in biosimilars over the past year concerned etanercept and adalimumab biosimilars and access to insulin.
December 30th 2021
With an FDA approval for a second insulin glargine biosimilar, the stage is set for stronger competition in 2022 with potential improved access and savings for patients.
December 25th 2021
Lannett hopes to initiate a pivotal trial of its insulin glargine biosimilar candidate, in anticipation of a launch in 2024.
December 23rd 2021
In Canada, a new jurisdiction inaugurates mandatory switching to biosimilars.
December 22nd 2021
From the approval of the first insulin glargine biosimilar (Semglee) to the potential for extreme biosimilar competition in the adalimumab market, 2021's regulatory stories were popular with readers.
December 21st 2021
The year 2021 brought several firsts in biosimilars and set the stage for expansion across therapeutic areas including diabetes and ophthalmology.
December 16th 2021
Investigators said more evidence would help to convince clinicians of the safety of switching between biosimilar products.
December 11th 2021
Tot Biopharm receives China regulatory approval for a bevacizumab biosimilar and Fujifilm moves forward with plans for a Suzhou Innovation and Collaboration Center.
